Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07098247

Exploring Photon-Counting CT for Enhanced Target Delineation and Dose Accuracy in Personalized Radiotherapy - ANTHEM

Radiotherapy remains a cornerstone of oncology care, particularly for rare or orphan cancers and chronic oncologic and rare non oncologic conditions, where precision and individualized treatment planning are necessary. Advances in imaging technologies are crucial to overcome the challenges posed by these cases, especially in achieving accurate tumor delineation and dose delivery. Photon-counting CT (PCCT) represents a transformative step forward in imaging technology. Unlike conventional energy-integrating CT, PCCT offers a) superior spatial resolution, enabling clearer visualization of tumor margins and fine anatomical structures, b) enhanced tissue characterization, allowing better differentiation between tumor tissues and normal tissue; c) spectral imaging capabilities, facilitating improved dose calculations. These attributes are particularly advantageous in high-precision radiotherapy techniques, such as stereotactic body radiotherapy (SBRT) or proton therapy, where small errors in target delineation or dose delivery can significantly impact treatment outcomes. However, very limited data reporting the clinical use of PCCT for RT planning are available.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

IRCCS Humanitas Research Hospital

Rozzano, Milan, 20089, Italy

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥18 years old patients
  • tumors located in challenging anatomical regions (brain, head and neck, liver, pancreas prostate), or Cardiac disease requiring RT by photon or proton at our Institution.

Exclusion criteria

  • 18 years old patients

Treatment and study plan

Primary outcomes

  1. Improve RT target delineation accuracy and differentiation of organs-at-risk (OARs).

    Time frame: day 1 (day of simulation TC)

    During the simulation, the investigator will evaluate the image quality obtained from photon-counting TC imaging compared to conventional imaging techniques, and assess how this improved imaging could enhance radiotherapy treatment planning. The data will be evaluated by indicative scores of imaging quality and treatement planning.

    minimum scale value is one and indicates a poor quality of the imaging - maximum scale value is five and indicates excellent image quality

Secondary outcomes

  1. Enhanced dose calculation precision, particularly for proton therapy

    Time frame: Day 1 (day of simulation TC)

    During the simulation, the investigator will evaluate the image quality obtained from photon-counting TC imaging compared to conventional imaging techniques, and assess how this improved imaging could enhance radiotherapy treatment planning. The data will be evaluated by indicative scores of imaging quality and treatement planning.

    minimum scale value is one and indicates a poor quality of the imaging - maximum scale value is five and indicates excellent image quality

Study contacts

Contact information is provided by the study sponsor or research team.

Research nurse

CONTACT

[email protected]

+39 0282248513

Research study coordinator

CONTACT

[email protected]

+39 0282247026

Sponsors and collaborators

Lead sponsor

Istituto Clinico Humanitas

Other

Registry information

Acronym: RAD4/RT_ANTHEM

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Aug 1, 2025
Registry last updated
Aug 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.